Acolyte Catheter System
IND- Indications
- Chronic total occlusion
Company intelligence / Profile preview
Simpson Interventions has developed the Acolyte™ Image Guided Crossing and Re-entry Catheter System, which received FDA Breakthrough Device Designation in March 2024. The system enables precise guidewire placement using real-time optical coherence tomography during procedures to treat coronary chronic total occlusions. The company also achieved Investigational Device Exemption from the FDA to begin clinical studies of Acolyte™, while its Shadow Catheter™, designed for guidewire exchange/access in coronary/peripheral arteries, received FDA 510(k) clearance. Early-stage clinical results are pending as pivotal trials are ongoing or planned.
1 more asset in the full pipeline.
Request access →Beyond the preview
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Follow clinical development from trial design and recruitment through results.
Explore licensing agreements, acquisitions, and the assets behind each deal.
Trace financing activity and the investors behind a company’s development.
Compare peer pipelines by target, modality, and therapeutic area.
Explore technology platforms and the patent landscape around relevant assets.
Connect company news and source material to the questions you’re investigating.
See how Gosset can support your research on Simpson Interventions.